MPA
MCID: MCR088
MIFTS: 51

Microscopic Polyangiitis (MPA)

Categories: Bone diseases, Cardiovascular diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Microscopic Polyangiitis

MalaCards integrated aliases for Microscopic Polyangiitis:

Name: Microscopic Polyangiitis 52 58 36 17 32
Microscopic Polyarteritis 58 71
Micropolyangiitis 58
Mpa 58

Characteristics:

Orphanet epidemiological data:

58
microscopic polyangiitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Germany),1-9/1000000 (Norway),1-9/100000 (United Kingdom),1-9/100000 (Germany),1-9/100000 (Australia),1-9/100000 (Japan),1-9/100000 (Kuwait),1-9/1000000 (Canada),1-9/100000 (Greece),1-9/1000000 (Lithuania),1-9/100000 (Sweden); Age of onset: Adult; Age of death: adult;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare circulatory system diseases
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases


Summaries for Microscopic Polyangiitis

KEGG : 36 Microscopic polyangiitis (MPA) is an idiopathic autoimmune disease characterized by systemic vasculitis. MPA predominantly affects small-calibre blood vessels and is associated with the presence of antineutrophil cytoplasmic autoantibodies (ANCA). The association with ANCAs originally defined the group of ANCA-associated vasculitides, comprising granulomatosis with polyangitis (GPA, formerly known as Wegener granulomatosis) [DS:H01655], microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly known as Churg-Strauss syndrome) [DS:H01468], which have different frequencies of ANCA-positivity. ANCA in MPA are predominantly directed against myeloperoxidase (MPO-ANCA) but may, in a minority of patients, be directed against proteinase 3 (PR3-ANCA). Not all patients, however, have ANCA. MPA is clinically characterized by small-vessel vasculitis primarily affecting the kidneys and the lungs but other organs may be involved as well. Renal involvement, which can be the only manifestation, is clinically apparent as rapidly progressive glomerulonephritis and histopathologically as pauci-immune necrotizing and crescentic glomerulonephritis. Diagnosis is mainly established by clinical manifestations, computed tomography (TC), ANCA antibody detection, and renal and pulmonary biopsy. The introduction of aggressive immunosuppressive treatment has substantially improved the prognosis. The standardized therapeutic regimen is based on cyclophosphamide and corticosteroids. Using this regimen, remission can be achieved in most of the patients. Rituximab may represent an important alternative to cyclophosphamide for patients who may not respond adequately to antimetabolite therapies.

MalaCards based summary : Microscopic Polyangiitis, also known as microscopic polyarteritis, is related to anca-associated vasculitis and vasculitis. An important gene associated with Microscopic Polyangiitis is MPO (Myeloperoxidase), and among its related pathways/superpathways are NF-kappaB Signaling and Toxoplasmosis. The drugs Methotrexate and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, kidney and lung, and related phenotypes are renal insufficiency and fever

NIH Rare Diseases : 52 Microscopic polyangiitis (MPA) is a disorder that causes blood vessel inflammation (vasculitis ), which can lead to organ damage. The kidneys, lungs, nerves, skin, and joints are the most commonly affected areas of the body. MPA is diagnosed in people of all ages, all ethnicities, and both genders. The cause of this disorder is unknown.

Wikipedia : 74 Microscopic polyangiitis is an ill-defined autoimmune disease characterized by a systemic, pauci-immune,... more...

Related Diseases for Microscopic Polyangiitis

Diseases related to Microscopic Polyangiitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 451)
# Related Disease Score Top Affiliating Genes
1 anca-associated vasculitis 32.3 MPO HLA-DRB1 CTLA4
2 vasculitis 31.4 TNF MPO CX3CL1 CTLA4
3 polyarteritis nodosa 31.3 MPO HLA-DRB1
4 churg-strauss syndrome 31.1 TNF MPO
5 granulomatosis with polyangiitis 30.5 TNF MPO CTLA4
6 mononeuropathy 30.5 TNF MPO
7 exanthem 30.2 TNF CTLA4
8 pleurisy 30.0 TNF MPO
9 goodpasture syndrome 30.0 MPO HLA-DRB1
10 graft-versus-host disease 30.0 TNF HLA-DRB1
11 aortitis 29.9 TNF MPO
12 membranous nephropathy 29.9 TNF MPO
13 granulocytopenia 29.9 TNF MPO
14 thyroiditis 29.9 TNF CTLA4
15 pharyngitis 29.8 TNF HLA-DRB1
16 nephrosclerosis 29.8 TNF MPO
17 appendicitis 29.8 TNF MPO
18 cryoglobulinemia 29.8 TNF HLA-DRB1
19 mixed connective tissue disease 29.8 TNF HLA-DRB1
20 cryptococcosis 29.8 TNF FCGR2A
21 skin sarcoidosis 29.7 TNF CTLA4
22 takayasu arteritis 29.7 TNF HLA-DRB1 FCGR2A
23 connective tissue disease 29.6 TNF HLA-DRB1 CTLA4
24 primary biliary cirrhosis 29.6 TNF HLA-DRB1 CTLA4
25 autoimmune disease 29.5 TNF HLA-DRB1 FCGR2A CTLA4
26 sclerosing cholangitis 29.5 TNF MPO HLA-DRB1
27 arthritis 29.5 TNF HLA-DRB1 CTLA4
28 conjunctivitis 29.4 TNF MPO
29 bronchiolitis obliterans 29.3 TNF MPO CTLA4
30 temporal arteritis 29.2 TNF MPO HLA-DRB1 CTLA4
31 juvenile rheumatoid arthritis 29.2 TNF HLA-DRB1 CTLA4
32 autoimmune hepatitis 29.2 TNF HLA-DRB1 CTLA4
33 hashimoto thyroiditis 29.2 TNF HLA-DRB1 CTLA4
34 thrombocytopenia 29.1 TNF FCGR2A CTLA4
35 rheumatoid vasculitis 29.0 TNF HLA-DRB1 CX3CL1
36 skin disease 28.9 TNF FCGR2A CTLA4
37 colitis 28.9 TNF MPO HLA-DRB1 CTLA4
38 lupus erythematosus 28.8 TNF HLA-DRB1 FCGR2A CTLA4
39 cholangitis 28.8 TNF MPO HLA-DRB1 CTLA4
40 central nervous system vasculitis 28.8 TNF MPO HLA-DRB1 CTLA4
41 asthma 28.1 TNF MPO HLA-DRB1 FCGR2A CTLA4
42 rheumatoid arthritis 27.5 TNF MPO HLA-DRB1 FCGR2A CX3CL1 CTLA4
43 systemic lupus erythematosus 27.4 TNF MPO HLA-DRB1 FCGR2A CX3CL1 CTLA4
44 glomerulonephritis 10.9
45 crescentic glomerulonephritis 10.6
46 rapidly progressive glomerulonephritis 10.6
47 allergic angiitis 10.6
48 idiopathic interstitial pneumonia 10.5
49 pulmonary fibrosis 10.5
50 endometrial cancer 10.5

Graphical network of the top 20 diseases related to Microscopic Polyangiitis:



Diseases related to Microscopic Polyangiitis

Symptoms & Phenotypes for Microscopic Polyangiitis

Human phenotypes related to Microscopic Polyangiitis:

58 31 (show all 38)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal insufficiency 58 31 hallmark (90%) Very frequent (99-80%) HP:0000083
2 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
3 skin rash 58 31 hallmark (90%) Very frequent (99-80%) HP:0000988
4 erythema 58 31 hallmark (90%) Very frequent (99-80%) HP:0010783
5 hematuria 58 31 hallmark (90%) Very frequent (99-80%) HP:0000790
6 autoimmunity 58 31 hallmark (90%) Very frequent (99-80%) HP:0002960
7 glomerulopathy 58 31 hallmark (90%) Very frequent (99-80%) HP:0100820
8 hemoptysis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002105
9 vasculitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002633
10 oliguria 58 31 hallmark (90%) Very frequent (99-80%) HP:0100520
11 nausea and vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002017
12 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
13 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
14 skin ulcer 58 31 frequent (33%) Frequent (79-30%) HP:0200042
15 gastrointestinal hemorrhage 58 31 frequent (33%) Frequent (79-30%) HP:0002239
16 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
17 venous thrombosis 58 31 frequent (33%) Frequent (79-30%) HP:0004936
18 diarrhea 58 31 frequent (33%) Frequent (79-30%) HP:0002014
19 subcutaneous hemorrhage 58 31 frequent (33%) Frequent (79-30%) HP:0001933
20 gastrointestinal infarctions 58 31 frequent (33%) Frequent (79-30%) HP:0005244
21 peritonitis 58 31 frequent (33%) Frequent (79-30%) HP:0002586
22 arthritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001369
23 subcutaneous nodule 58 31 occasional (7.5%) Occasional (29-5%) HP:0001482
24 arrhythmia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011675
25 sinusitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000246
26 congestive heart failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001635
27 pericarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001701
28 gangrene 58 31 occasional (7.5%) Occasional (29-5%) HP:0100758
29 pancreatitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001733
30 paresthesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003401
31 uveitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000554
32 epistaxis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000421
33 cutis marmorata 58 31 occasional (7.5%) Occasional (29-5%) HP:0000965
34 episcleritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100534
35 abnormal retinal vascular morphology 31 occasional (7.5%) HP:0008046
36 peripheral neuropathy 58 Occasional (29-5%)
37 abnormality of the retinal vasculature 58 Occasional (29-5%)
38 increased inflammatory response 58 Very frequent (99-80%)

Drugs & Therapeutics for Microscopic Polyangiitis

Drugs for Microscopic Polyangiitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
2
leucovorin Approved Phase 4 58-05-9 6006 143
3
Mycophenolic acid Approved Phase 4 24280-93-1 446541
4
rituximab Approved Phase 4 174722-31-7 10201696
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
8
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
9
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
11
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
12 Dermatologic Agents Phase 4
13 Folic Acid Antagonists Phase 4
14 Vitamin B Complex Phase 4
15 Vitamin B9 Phase 4
16 Folate Phase 4
17 Antitubercular Agents Phase 4
18 Anti-Infective Agents Phase 4
19 Antibiotics, Antitubercular Phase 4
20 Anti-Bacterial Agents Phase 4
21 Gastrointestinal Agents Phase 4
22 Methylprednisolone Acetate Phase 4
23 glucocorticoids Phase 4
24 Antiemetics Phase 4
25 Hormone Antagonists Phase 4
26 Neuroprotective Agents Phase 4
27 Anti-Inflammatory Agents Phase 4
28 Autonomic Agents Phase 4
29 Antineoplastic Agents, Hormonal Phase 4
30 Hormones Phase 4
31 Tin Fluorides Phase 4
32
belimumab Approved Phase 3 356547-88-1 5957 10451420
33
Acetaminophen Approved Phase 3 103-90-2 1983
34
Clemastine Approved, Investigational Phase 3 15686-51-8 26987
35
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
36
Azathioprine Approved Phase 3 446-86-6 2265
37
Dexchlorpheniramine Experimental, Investigational Phase 3 25523-97-1 33036
38 Plasma Substitutes Phase 3
39 Antibodies, Antineutrophil Cytoplasmic Phase 3
40 Antimetabolites Phase 3
41 Immunoglobulin G Phase 3
42 Rho(D) Immune Globulin Phase 3
43 Immunoglobulins, Intravenous Phase 3
44 gamma-Globulins Phase 3
45
Infliximab Approved Phase 2 170277-31-3
46
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
47
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
48
Ethanol Approved Phase 2 64-17-5 702
49
Pirfenidone Approved, Investigational Phase 2 53179-13-8 40632
50
Abatacept Approved Phase 2 332348-12-6 10237

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors a Prospective Randomized Study in 125 Patients Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
2 Alemtuzumab for ANCA Associated Refractory Vasculitis - a Study of Safety and Efficacy Unknown status NCT01405807 Phase 4 Alemtuzumab
3 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
4 Short-Course Glucocorticoids and Rituximab in ANCA-Associated Vasculitis Completed NCT02169219 Phase 4 Glucocorticoids;Rituximab
5 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
6 A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis Recruiting NCT02115997 Phase 4 Methylprednisolone;Prednisone;Rituximab
7 Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial Recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
8 Comparative Study of the Efficacy of Induction Therapy With Cyclophosphamide or Mycophenolate Mofetil for Non-Life-Threatening Relapses of PR3- or MPO-ANCA Associated Vasculitis Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
9 Treatment of ANCA-Associated Vasculitides : Corticosteroids and Pulse Cyclophosphamide Followed by Maintenance Therapy With Methotrexate or Azathioprine: a Prospective Multicenter Randomized Trial Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
10 A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis Completed NCT01663623 Phase 3 Azathioprine
11 Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
12 Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial Completed NCT00987389 Phase 3 Glucocorticoids
13 Randomized Trial of Intravenous Pulse Versus Oral Continuous Cyclophosphamide for Induction of Remission in Systemic ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
14 Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI) Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
15 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
16 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II Completed NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
17 Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study Recruiting NCT02807103 Phase 3 Rituximab;Placebo-rituximab;Cyclophosphamide;Placebo-cyclophosphamide
18 Evaluating Favorable, Immunological Effects of Rituximab With Cyclophosphamide Compared to Rituximab Alone in AAV Patients Recruiting NCT03942887 Phase 3 Rituximab;endoxan;Methylprednisolone;Prednisolone
19 Extended Follow Up of the Mainritsan 2 Study. Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab: a Placebo- Controlled Randomized Trial Active, not recruiting NCT02433522 Phase 3 rituximab;Placebo
20 An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis Active, not recruiting NCT01697267 Phase 3 Azathioprine
21 Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis Not yet recruiting NCT03920722 Phase 3 Rituximab;placebo
22 Intravenous Immunoglobulin After Relapse in Vasculitis (Microscopic Polyangiitis, Wegener’s Granulomatosis and SHURG-STRAUSS Syndrome) During and After Corticosteroids and Immunosuppressant Therapies a Multicenter Prospective Trial Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
23 Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis Terminated NCT00307645 Phase 3 Cyclophosphamide;Mycophenolate mofetil;Azathioprine;Prednisone (and methylprednisolone)
24 Randomised Trial of Plasma Exchange or High Dose Methyl Prednisolone as Adjunctive Therapy for Severe Renal Vasculitis Terminated NCT01408836 Phase 2, Phase 3 Intravenous methyl prednisolone;Methyl prednisolone
25 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial. Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
26 A Phase IIA, International, Multicenter, Open-label, Uncontrolled Study to Evaluate The Safety And Pharmacokinetics of 4 × 375 mg/m2 Intravenous Rituximab in Pediatric Patients With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Completed NCT01750697 Phase 2 Rituximab
27 Phase II Pilot Cohort Study to Investigate the Safety and Efficacy of Infliximab as Additional Therapy in the Treatment if Anti-Neutrophil Cytoplasm Antibody Associated Vasculitis Completed NCT00753103 Phase 2 Cyclophosphamide;Prednisolone;Azathioprine;Mycophenolate mofetil;Methylprednisolone
28 An Open Trial of the Efficacy of Glucocorticoids and Methotrexate (MTX) in the Treatment of Systemic Vasculitis Completed NCT00001256 Phase 2 prednisone and methotrexate
29 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Efficacy and Safety Study of IFX-1 in Add-On to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Recruiting NCT03712345 Phase 2 IFX-1;IFX-1;Placebo
30 A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Recruiting NCT03895801 Phase 2 IFX-1;Placebo-IFX-1;Glucocorticoid (GC);Placebo-Glucocorticoid (Placebo-GC)
31 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
32 A Pilot Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Pulmonary Fibrosis With Anti-myeloperoxydase (MPO) Antibodies or With Anti-MPO Associated Vasculitis." Recruiting NCT03385668 Phase 2 Pirfenidone
33 A Pilot Study Examining the Effect of Abatacept in ANCA Associated Vasculitis Terminated NCT00482066 Phase 2 Abatacept (Orencia)
34 A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis Withdrawn NCT01598857 Phase 2 Blisibimod;Placebo
35 A Pilot Study of Mycophenolate Mofetil (MMF) in Patients With p-ANCA Microscopic Polyangiitis and Mild to Moderate Renal Dysfunction. Completed NCT00405860 Phase 1 CellCept (mycophenolate mofetil)
36 High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome Terminated NCT00278512 Phase 1 Cyclophosphamide;ATG (rabbit);G-CSF;Campath-1h;Fludarabine;Tacrolimus;Mesna
37 Cohort Study of Chinese Patients With Pulmonary Vasculitis Unknown status NCT02126098
38 A Qualitative Study Using Interviews With Patients Who Have Anti-neutrophil Cytoplasm Antibody (ANCA) Associated Vasculitis, to Develop a Patient Reported Outcome (PRO) Measure Unknown status NCT01729624
39 ACR/EULAR Endorsed Study to Develop New Diagnostic and Classification Criteria for Primary Systemic Vasculitis Unknown status NCT01066208
40 Eosinophilic Granulomatosis With Polyangiitis Cohort Unknown status NCT03036670
41 Neutrophils Function and Identification of Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis). Unknown status NCT01862068
42 Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides With Positive ANCA After Relapse or Resistant Immunosuppressant Therapies Completed NCT00307593 Infliximab;Rituximab
43 Prospective, Observational Safety Study of Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Treated With Rituximab Completed NCT01613599 Rituximab
44 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
45 VCRC Validation of Patient-Reported Diagnostic Data Completed NCT02190942
46 Educational Needs of Patients With Systemic Vasculitis- an International Survey Completed NCT02190929
47 Illness Perception, Fatigue, and Function in Systemic Vasculitis (The VCRC Vasculitis Perception (VIP) Study) Completed NCT02190916
48 The Journey of Patients With Vasculitis From First Symptom to Diagnosis Completed NCT03410290
49 The ANCA Vasculitis Questionnaire (AAV-PRO©) Completed NCT02507024
50 Impact of Vasculitis on Employment and Income. An Online Survey of Participants in the VCRC Patient Contact Registry Completed NCT02476292

Search NIH Clinical Center for Microscopic Polyangiitis

Genetic Tests for Microscopic Polyangiitis

Anatomical Context for Microscopic Polyangiitis

MalaCards organs/tissues related to Microscopic Polyangiitis:

40
Neutrophil, Kidney, Lung, Skin, Heart, Testes, Endothelial

Publications for Microscopic Polyangiitis

Articles related to Microscopic Polyangiitis:

(show top 50) (show all 1763)
# Title Authors PMID Year
1
An overlap of antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis and IgG4-related kidney disease. 61
31805271 2020
2
Rituximab utilization for approved and off-label nononcology indications and patients' experiences with the Patient Alert Card. 61
31911839 2020
3
No evident association of nasal carriage of Staphylococcus aureus or its small-colony variants with cotrimoxazole use or ANCA-associated vasculitis relapses. 61
31834404 2020
4
Vasculitis and the ear: a literature review. 61
31599796 2020
5
Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor. 61
31570253 2020
6
[Anti B-cell-antibody treatment for maintenance of remission in granulomatosis with polyangiitis and microscopic polyangiitis]. 61
31914468 2020
7
ANCA-Associated Vasculitis: Core Curriculum 2020. 61
31358311 2020
8
Treatment and its side effects in ANCA-associated vasculitides - Study based on POLVAS registry data. 61
31958704 2020
9
Rationale of concomitant cyclophosphamide for remission-induction in patients with antineutrophil cytoplasmic antibody-associated vasculitis: A propensity score-matched analysis of two nationwide prospective cohort studies. 61
31859544 2020
10
Clinical implication of chronic paranasal sinusitis for the classification of microscopic polyangiitis. 61
31573728 2020
11
Acute Myocarditis in Patients with Antineutrophil Cytoplasmic Antibody-positive Microscopic Polyangiitis and Receiving Rituximab Therapy. 61
31676698 2019
12
Remission maintenance in ANCA-associated vasculitis: does one size fit all? 61
31762340 2019
13
Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway. 61
31859355 2019
14
Spectrum and prognosis of ANCA-associated vasculitis-related bronchiectasis: data from 61 patients. 61
31787599 2019
15
Childhood GPA, EGPA, and MPA. 61
31837445 2019
16
Evaluation of 12 different assays for detecting ANCA in Chinese patients with GPA and MPA: a multicenter study in China. 61
31414304 2019
17
Phlebectasia in a finger in a case of microscopic polyangiitis with peripheral polyneuropathy. 61
28838824 2019
18
Multiple Gastrointestinal Ulcers in a Patient With Microscopic Polyangiitis: A Clinical Image. 61
31714301 2019
19
Clinical Effect of Alpha-1 Antitrypsin Deficiency in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Results from a French Retrospective Monocentric Cohort. 61
30824651 2019
20
Peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitides: Insights from the DCVAS study. 61
31540965 2019
21
An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea. 61
31852583 2019
22
Nonatherosclerotic Abdominal Vasculopathies. 61
31200053 2019
23
Do ANCA-associated vasculitides and IgG4-related disease really overlap or not? 61
31571413 2019
24
Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification. 61
30805643 2019
25
Severe Functional Loss of the Hand due to Necrotizing Fasciitis with Underlying Vasculitis Neuropathy. 61
31616126 2019
26
Recognizing Central Nervous System Involvement as a Progressive Feature of Microscopic Polyangiitis: A Diagnostic Dilemma. 61
30986393 2019
27
Contrast Enhanced Computed Tomography Revealed Gallbladder Hemorrhage Due to Active Vasculitis in a Patient With Microscopic Polyangiitis. 61
29561470 2019
28
Microscopic polyangiitis in a case of silica exposure: a rare presentation. 61
31505920 2019
29
Noninfective endocarditis in microscopic polyangiitis: Report of a case with a successful response to immunosuppressive therapy. 61
28822626 2019
30
Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. 61
30102330 2019
31
Update on the Management of Respiratory Manifestations of the Antineutrophil Cytoplasmic Antibodies-Associated Vasculitides. 61
31376892 2019
32
Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. 61
30887055 2019
33
Malignancies in patients with ANCA-associated vasculitis - A population based cohort study. 61
31474595 2019
34
The color of skin: purple diseases of the skin, nails, and mucosa. 61
31896408 2019
35
Clinical characteristics and outcomes in microscopic polyangiitis patients with renal involvement: a study of 124 Chinese patients. 61
31477033 2019
36
Microscopic polyangiitis masquerading as a pancreatic neoplasm with multiple lung metastases. 61
31434674 2019
37
Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Is There Still a Role for Cyclophosphamide? 61
31277751 2019
38
Epidemiology and clinical features of childhood-onset anti-neutrophil cytoplasmic antibody-associated vasculitis: a clinicopathological analysis. 61
31076873 2019
39
Significant association between clinical characteristics and immuno-phenotypes in patients with ANCA-associated vasculitis. 61
31377799 2019
40
[ANCA-associated vasculitides : State of the art]. 61
31028473 2019
41
Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis. 61
31308208 2019
42
Incidence and prevalence of granulomatosis with polyangiitis and microscopic polyangiitis in health management organization in Argentina: a 15-year study. 61
30746579 2019
43
Clinical features and prognosis of microscopic polyangiitis with usual interstitial pneumonia compared with idiopathic pulmonary fibrosis. 61
31013398 2019
44
Reactivation of latent cytomegalovirus infection in patients with rheumatologic disease: a case-control study. 61
31076831 2019
45
The presence of anti-neutrophil extracellular trap antibody in patients with microscopic polyangiitis. 61
30897615 2019
46
Neurological Manifestations Do not Affect Cumulative Survival in Indian Patients with Antineutrophil Cytoplasmic Antibody Associated Vasculitis. 61
31512630 2019
47
Distinction between MPO-ANCA and PR3-ANCA-associated glomerulonephritis in Chinese patients: a retrospective single-center study. 61
30737591 2019
48
Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist. 61
31242923 2019
49
Fibrosis-4 index at diagnosis is associated with all-cause mortality in patients with microscopic polyangiitis and granulomatosis with polyangiitis. 61
31196158 2019
50
Plasma Exchange Therapy to Reduce Mortality in Japanese Patients With Diffuse Alveolar Hemorrhage and Microscopic Polyangiitis. 61
31233282 2019

Variations for Microscopic Polyangiitis

Expression for Microscopic Polyangiitis

Search GEO for disease gene expression data for Microscopic Polyangiitis.

Pathways for Microscopic Polyangiitis

GO Terms for Microscopic Polyangiitis

Cellular components related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.8 TNF HLA-DRB1 CTLA4

Biological processes related to Microscopic Polyangiitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of smooth muscle cell proliferation GO:0048661 9.4 TNF CX3CL1
2 negative regulation of T cell proliferation GO:0042130 9.37 HLA-DRB1 CTLA4
3 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.32 TNF CX3CL1
4 negative regulation of interleukin-6 production GO:0032715 9.26 TNF CX3CL1
5 microglial cell activation GO:0001774 9.16 TNF CX3CL1
6 defense response GO:0006952 9.13 TNF MPO CX3CL1
7 immune response GO:0006955 8.92 TNF HLA-DRB1 CX3CL1 CTLA4

Sources for Microscopic Polyangiitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....